Biotech Startups

Unoentrecienmil is a Spanish research foundation that funds investigative projects focused on finding a cure for childhood leukemia through annual research grants.

1 investor

FungiFix uses mycoremediation to remove contaminants from polluted soil, then transforms the fungal biomass into sustainable biofillers for concrete. The company targets contaminated land remediation in states like California, combining environmental restoration with sustainable construction materials.

1 investor

FungiLife produces high-performance sophorolipids, a fungal biosurfactant made through a scalable liquid-state fermentation process using a proprietary fungus. It supplies 100% biodegradable biosurfactants to industries including oil and gas, industrial and home cleaning, cosmetics, agriculture, and bioremediation.

1 investor

Fungit develops microorganism-based biocontrol agents, using fungal microorganisms to extend the shelf life of fruits and vegetables and protect crops in pre-harvest and post-harvest agriculture. It serves growers and packagers as an alternative to chemical fertilizers and pesticides, and is based in Israel.

1 investor

Fuse Vectors develops AAV manufacturing platforms for biotech researchers and developers, enabling efficient production from early discovery screening through preclinical validation to clinical-grade manufacturing.

1 investor

Fusion Genomics' ONETest platform integrates targeted metagenomic sequencing with artificial intelligence-driven analysis to identify microbial pathogens from clinical specimens, serving hospital laboratories and critical-care teams for complex infection diagnosis.

1 investor

Fusion Antibodies optimizes antibody development for research and therapeutic applications. The company serves pharmaceutical and biotech customers seeking to enhance antibody performance.

1 investor

Futura Genomics provides accredited genetic testing services that deliver personalized health and ancestry insights tailored to diverse populations, with particular focus on African heritage. The company partners customers with medical professionals and wellness specialists to translate genetic data into actionable health recommendations.

1 investor

FuturedMe develops small-molecule drug candidates using CANDDY, a protein-degradation platform licensed from Tokyo University of Science that induces direct proteasomal degradation of disease-related proteins instead of inhibiting them. The company aims to create therapies for patients with previously undruggable targets and no existing treatment options.

1 investor

Fuzionaire develops chemistry technology based on Earth-abundant alkali metal catalysts and reagents (its ionic alkali metal / IAM platform) for applications in medicine, energy, and materials. The platform originated from discoveries at Caltech, UCLA, and other institutions and targets molecular-level innovation across pharmaceuticals, clean energy, and advanced materials.

1 investor

Fuzionaire Theranostics develops radiopharmaceuticals for oncology using its HetSiFA silicon (SiFA) chemistry platform, creating chemically matched fluorine-18 PET diagnostic and radioligand therapy pairs. Its lead program, FTX-426, targets GRPR-expressing solid tumors such as prostate and breast cancer.

1 investor

Fyodor Biosciences develops innovative diagnostics, medicines, and healthcare solutions with a focus on accessible global health. The company is led by scientists and health leaders with expertise in biomedical research and biotechnology.

1 investor

FYR develops a platform to analyze extracellular vesicles from blood samples and generate multiomics insights for disease understanding and personalized treatment selection. The company serves biomedical researchers, drug developers, and clinical diagnostics organizations.

1 investor

Fyteko is an agricultural technology company focused on sustainability in farming.

1 investor

Fziomed develops proprietary dual-polymer gel technology for use across multiple surgical applications. The company focuses on providing innovative solutions for surgical procedures.

1 investor

Designs, produces and installs portable clean rooms

1 investor

G2GBIO (Good to the Globe Biotech) is a pharmaceutical company developing improved new drug injectable formulations, with platform technology applicable to treatments for various diseases and mass-production techniques. It focuses on supplying medicines under a "Humanity First" vision.

1 investor

Gabar (Gabarx) is a biopharmaceutical company developing small-molecule drug candidates for central nervous system disorders such as anxiety and depression, drawing on deuterium-modified molecule chemistry. Its work spans clinical development, regulatory strategy, and CMC/quality across multiple therapeutic indications.

1 investor

Galam is a global company that develops and produces raw materials, flavors, and food additives for food and beverage manufacturers, pet food producers, and industrial applications. Operating through two divisions—one focused on innovative food technology solutions including sugar reduction and fiber enrichment, and another producing starches, syrups, and specialty ingredients—the company serves thousands of customers across over 60 countries.

1 investor

Galdieria is a microalga species that produces a precious metal adsorbent material derived from its dried cells, designed for metal recovery in recycling and artisanal gold mining operations. The company manufactures and refines these biosorbent materials to extract precious metals from dilute solutions and mineral ores while enabling safer, toxin-free processing in small-scale mining contexts.

1 investor

Galen builds causal, computational models of living cells ("virtual cells") that aim to predict how a cell changes under a given intervention before experiments are run. Its initial focus is durability and exhaustion in engineered T cell therapies, serving scientists and drug developers working on cell therapies.

1 investor

Galenica distributes Leica confocal microscopes for biomedical research, enabling high-precision imaging of subcellular structures and dynamic cellular processes at nanoscopic resolution.

1 investor

Galenvs is a contract research organization offering design, development, testing, and bio-manufacturing services for healthcare and industrial customers. The company applies multidisciplinary technologies and data-driven approaches to enzyme engineering, carbon capture, and therapeutic development.

1 investor

Inventum Biotech develops software solutions for analytical, multimodal, and AI-based applications focused on preventing and managing non-communicable diseases using data and analytics.

1 investor